Title:Current Status of Novel Pyridine Fused Derivatives as Anticancer Agents: An Insight into Future Perspectives and Structure Activity Relationship (SAR)
Volume: 21
Issue: 25
Author(s): Ajay Manaithiya, Ozair Alam*, Vrinda Sharma, Mohd. Javed Naim, Shruti Mittal, Faizul Azam, Asif Husain, Aadil Ahmad Sheikh, Mohd. Imran and Imran A. Khan
Affiliation:
- Medicinal Chemistry and Molecular Modelling Lab, Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062,India
Keywords:
Anticancer activity, Pyridine fused derivatives, SAR, Docking, Future perspectives, SAR.
Abstract: Cancer is a heterogeneous disease characterized by an abnormal and uncontrolled division
of the cells leading to tumors that invade the adjacent normal tissues. After cardiovascular diseases, it
is the second most prevalent disease accounting for one in every six deaths worldwide. This alarming
rate thus, demands an urgent need to investigate more effective drugs to combat the said disease.
Oxygen and nitrogen-based heterocyclic compounds have shown remarkable therapeutic activity
towards several diseases, including cancer. In this review, we have attempted to summarize the work
done in the last decade (2009-2019), highlighting the anticancer activity of pyrido fused fivemembered
heterocyclic ring derivatives. Additionally, we have focused on seven heterocyclic pyridine
fused rings: Imidazopyridine, Triazolopyridine, Pyrrolopyridine, Pyrazolopyridines, Thienopyridine,
and Isoxazolopyridine. A total of forty-nine compounds have been studied based on their invitro
cytotoxic activity and their structure-activity relationship, underlining the anticancer activity of
their various pharmacophores and substituents. This review, therefore, aims to draw the attention of
the researchers worldwide towards the enormous scope of development of heterocyclic drug compounds,
focussing mainly on pyrido fused five-membered heterocyclic rings as anticancer drugs.
